Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellular Matrix-BCT-HA versus vaginal estriol for genitourinary syndrome of menopause
2023-507200-31-00Phase 4Completed
- Sponsor
- Fundació Santiago Dexeus Font
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of estriol, platelet-rich plasma and hyaluronic acid in vaginal atrophy (2 arms), sponsored by Fundació Santiago Dexeus Font. Primary endpoint: Primary efficacy: improvement in symptomatology by VHIS at 6 months. Started May 2024; status: completed.
02
Drugs
estriolplatelet-rich plasmahyaluronic acid
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on 2023-507200-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507200-31-00.